# CRISPR Therapeutics (CRSP) — Analyst Forecast

CRSP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/crsp/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 10 | 0 | 23 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $52.00 | $75.50 | $88.00 | 4 |

Last price $51.52 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | UBS | Initiated Coverage | Neutral | $52.00 |
| Aug 31, 2026 | Needham | Maintained | Buy | $82.00 |
| Aug 31, 2026 | Citizens | Maintained | Market Outperform | $80.00 |
| Aug 25, 2026 | Citizens | Maintained | Market Outperform | $80.00 |
| Aug 4, 2026 | Citigroup | Maintained | Buy | $88.00 |
| Jul 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $80.00 |
| Jul 6, 2026 | Citizens | Maintained | Market Outperform | $80.00 |
| May 13, 2026 | Bernstein | Maintained | Market Perform | $56.00 |
| May 6, 2026 | Citigroup | Maintained | Buy | $82.00 |
| Mar 17, 2026 | Piper Sandler | Maintained | Overweight | $110.00 |
| Feb 17, 2026 | Chardan Capital | Maintained | Buy | $76.00 |
| Feb 13, 2026 | Needham | Maintained | Buy | $82.00 |
| Feb 13, 2026 | Evercore ISI Group | Maintained | Outperform | $74.00 |
| Feb 13, 2026 | TD Cowen | Maintained | Hold | $45.00 |
| Jan 30, 2026 | Citizens | Maintained | Market Outperform | $80.00 |
| Dec 23, 2025 | Needham | Maintained | Buy | $80.00 |
| Dec 23, 2025 | Citizens | Maintained | Market Outperform | $86.00 |
| Nov 26, 2025 | Chardan Capital | Maintained | Buy | $74.00 |
| Nov 12, 2025 | Citigroup | Maintained | Buy | $77.00 |
| Nov 11, 2025 | Baird | Maintained | Neutral | $44.00 |

## Frequently Asked Questions

### What is the price target for CRSP stock?

The average 12-month analyst price target for CRISPR Therapeutics (CRSP) is $75.50, with a high estimate of $88.00 and a low of $52.00, across 4 analysts.

### Is CRSP a buy, sell, or hold?

Analysts covering CRISPR Therapeutics currently average a Buy rating: 13 buy, 10 hold and 0 sell, from 23 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for CRSP?

The average price target of $75.50 implies 46.55% upside from the last price of $51.52.

### What is the latest analyst rating on CRSP?

On Oct 15, 2026, UBS initiated coverage of CRISPR Therapeutics at Neutral with a price target of $52.00.

## Similar Stocks

- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [KALA](https://www.lighthorse.io/tickers/kala) — KALA BIO, Inc. - Common Stock
- [BEAM](https://www.lighthorse.io/tickers/beam) — Beam Therapeutics Inc. - Common Stock
- [ALLO](https://www.lighthorse.io/tickers/allo) — Allogene Therapeutics, Inc. - Common Stock
- [AXSM](https://www.lighthorse.io/tickers/axsm) — Axsome Therapeutics, Inc. - Common Stock
- [EDIT](https://www.lighthorse.io/tickers/edit) — Editas Medicine, Inc. - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).